Skip to main content
|
  1. Home
  2. Clinical Trials
  3. M25-274

Telisotuzumab Vedotin as a Monotherapy in Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Short Title: M25-274


Enrollment Status: Recruiting

NCT #: NCT06568939

Specialty Area: Oncology

Condition Studied: Non-Small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: II


Study Information

Summary / Purpose

To find out how safe telisotuzumab vedotin is and how it affects cancer activity in people with previously treated non-squamous non-small cell lung cancer.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with non-squamous Non-Small Cell Lung Cancer (NSCLC) that has overexpression of c-Met
  • Must have received prior treatment for NSCLC

What's Involved

Participation in the study will include:
  • Intravenous (IV) infusion with telisotuzumab vedotin at one of three dose levels
  • Regular clinic visits for medical assessments and monitoring
  • Blood tests and imaging to monitor your health, treatment effects, and response to treatment
  • Questionnaires

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06568939

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up